MedTrace Logo

Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

NCT03895034 · Status: COMPLETED · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-05-12

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate, for the visual correction of aphakia, whether the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) can be used to improve visual outcomes after performing adjustments of the LAL with the LDD. This is an exploratory study. No primary effectiveness endpoints will be identified.

Conditions

  • Aphakia
  • Cataract

Interventions

DEVICE

Light Adjustable lens (LAL) and Light Delivery Device (LDD)

Eligible eyes will receive Light adjustable lens with Light delivery Device treatments

Sponsors & Collaborators

  • RxSight, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-14
Primary Completion
2020-03-01
Completion
2020-03-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03895034 on ClinicalTrials.gov